Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
Blaž Grošelj, Nitin Sharma, Freddie C. Hamdy, et al.
British Journal of Cancer (2013) Vol. 108, Iss. 4, pp. 748-754
Open Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

The molecular hallmarks of epigenetic control
C. David Allis, Thomas Jenuwein
Nature Reviews Genetics (2016) Vol. 17, Iss. 8, pp. 487-500
Closed Access | Times Cited: 2313
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 589
Targeting DNA damage response in cancer therapy
Noriko Hosoya, Kiyoshi Miyagawa
Cancer Science (2014) Vol. 105, Iss. 4, pp. 370-388
Open Access | Times Cited: 279
Cancer epigenetics in clinical practice
Verónica Dávalos, Manel Esteller
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 4, pp. 376-424
Open Access | Times Cited: 155
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Lourdes Hontecillas‐Prieto, Rocío Flores-Campos, Andrew Silver, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 142
Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT
Lingpu Zhang, Jia‐Zhen Yang, Jia Huang, et al.
Chem (2024) Vol. 10, Iss. 5, pp. 1337-1356
Closed Access | Times Cited: 21
Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation
Fade Gong, Kyle M. Miller
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis (2013) Vol. 750, Iss. 1-2, pp. 23-30
Closed Access | Times Cited: 161
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu, Yichao Wan, Yuliang Xiao, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8977-9002
Closed Access | Times Cited: 130
Cancer biomarker discovery: Current status and future perspectives
Katrin Mäbert, Monica Cojoc, Claudia Peitzsch, et al.
International Journal of Radiation Biology (2014) Vol. 90, Iss. 8, pp. 659-677
Closed Access | Times Cited: 119
Targeting Histone Deacetylases in Diseases: Where Are We?
Rosaria Benedetti, Mariarosaria Conte, Lucia Altucci
Antioxidants and Redox Signaling (2014) Vol. 23, Iss. 1, pp. 99-126
Open Access | Times Cited: 112
Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting
J. Biau, Emmanuel Chautard, Pierre Verrelle, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 107
The impact of tumour pH on cancer progression: strategies for clinical intervention
Carol Ward, James Meehan, Mark Gray, et al.
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 2, pp. 71-100
Open Access | Times Cited: 107
Epigenomes as therapeutic targets
Christopher A. Hamm, Fabrício F. Costa
Pharmacology & Therapeutics (2015) Vol. 151, pp. 72-86
Closed Access | Times Cited: 103
How do tumor cells respond to HDAC inhibition?
Andrea Newbold, Katrina J. Falkenberg, H. Miles Prince, et al.
FEBS Journal (2016) Vol. 283, Iss. 22, pp. 4032-4046
Open Access | Times Cited: 103
DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers
Ching-Yu Yen, Hurng-Wern Huang, Chih‐Wen Shu, et al.
Cancer Letters (2016) Vol. 373, Iss. 2, pp. 185-192
Closed Access | Times Cited: 102
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Thomas J. Galloway, Lori J. Wirth, A. D. Colevas, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 7, pp. 1566-1573
Open Access | Times Cited: 93
Preserving genome integrity and function: the DNA damage response and histone modifications
Jae Jin Kim, Seo Yun Lee, Kyle M. Miller
Critical Reviews in Biochemistry and Molecular Biology (2019) Vol. 54, Iss. 3, pp. 208-241
Open Access | Times Cited: 85
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, et al.
JCI Insight (2023) Vol. 8, Iss. 7
Open Access | Times Cited: 39
The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy
Brendan Moran, Maria Davern, John V. Reynolds, et al.
Cancer Letters (2023) Vol. 559, pp. 216121-216121
Open Access | Times Cited: 39
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
Bingbing Hao, Ke Ma, Junyu Xu, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 6, pp. 1305-1315
Closed Access | Times Cited: 9
Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo
Hui‐Wen Chiu, Ya-Ling Yeh, Yi‐Ching Wang, et al.
PLoS ONE (2013) Vol. 8, Iss. 10, pp. e76340-e76340
Open Access | Times Cited: 82
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
Carine Robert, Pratik Nagaria, Nisha R. Pawar, et al.
Leukemia Research (2016) Vol. 45, pp. 14-23
Open Access | Times Cited: 76
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Gloria Manzotti, Alessia Ciarrocchi, Valentina Sancisi
Cancers (2019) Vol. 11, Iss. 3, pp. 304-304
Open Access | Times Cited: 74
Radiosensitising Nanoparticles as Novel Cancer Therapeutics — Pipe Dream or Realistic Prospect?
Jonathan A. Coulter, Wendy B. Hyland, James R. Nicol, et al.
Clinical Oncology (2013) Vol. 25, Iss. 10, pp. 593-603
Open Access | Times Cited: 73
Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?
Carsten Herskind, Chris J. Talbot, Sarah L. Kerns, et al.
Cancer Letters (2016) Vol. 382, Iss. 1, pp. 95-109
Open Access | Times Cited: 71
Page 1 - Next Page

Scroll to top